Navigation Links
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Date:6/8/2008

Oral presentation at international lymphoma conference shows investigational regimen resulted in 82 percent overall survival and 78

percent progression-free survival rates in patients receiving

radioimmunotherapy Confirmatory phase III clinical trial is presently being conducted in this

patient population

LUGANO, Switzerland, June 9 /PRNewswire-FirstCall/ -- In an oral presentation today at the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland, Paul A. Hamlin, M.D., of Memorial Sloan-Kettering Cancer Center, presented results of an investigator-sponsored trial of the investigational regimen consolidating rituximab-CHOP (R-CHOP) with 90Yttrium Ibritumomab Tiuxetan (Zevalin(R)) radioimmunotherapy in high risk, elderly patients with previously untreated high-intermediate and high risk diffuse large B-cell lymphoma (DLBCL). Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) markets Zevalin in the United States.

"In a high risk, elderly patient population with significant comorbidities, sequential R-CHOP followed by radioimmunotherapy resulted in excellent complete response and overall and progression-free survival rates," concluded Hamlin. "This approach is now the focus of an international phase III study."

"Improvement of relapse-free survival in these patients is an important unmet need since the outcome is poor for patients who relapse with this disease and who cannot tolerate intensive salvage therapy and stem cell transplantation," said Jack W. Singer, M.D., Chief Medical Officer at CTI. "The survival data from this study are highly encouraging compared to historical data and provide the rationale for a registration-directed randomized trial of Zevalin consolidation in higher risk patients with DLBCL."

Results of the Study

Historical studies provided as background in the presentation indicate that approximately 50 perc
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
2. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
6. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
7. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
8. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
9. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
(Date:1/23/2015)... Jan. 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ... the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with ... and provides an update for shareholders detailing why a "YES" ... Dear Shareholders, As we reflect upon ...
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... manufacturer of the popular and successful Menaflex Collagen Meniscus implant, ... of a hearing under 21 CFR Part 16 before the ... According to ReGen Chair and CEO Gerald E. ... the past six years makes it clear that any such ...
... March 22, 2011 UBM Canon,s Medical Device Media ... ( European Medical Device Technology ), MD+DI ... the world,s only 100% qualified medical device ... virtual conference and tradeshow focusing on current and emerging ...
Cached Medicine Technology:ReGen to FDA: 'Thanks, But No Thanks' 2ReGen to FDA: 'Thanks, But No Thanks' 3ReGen to FDA: 'Thanks, But No Thanks' 4EMDT, MD+DI, and Qmed Announce Virtual Event Dedicated to Developments in Materials for Medical Applications 2EMDT, MD+DI, and Qmed Announce Virtual Event Dedicated to Developments in Materials for Medical Applications 3EMDT, MD+DI, and Qmed Announce Virtual Event Dedicated to Developments in Materials for Medical Applications 4
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release of ... kids with cancer. The Chemo Duck App, available on iTunes for ... games to help children of all ages living with cancer adjust ... kids entertained, educated and at ease while waiting for clinic visits ...
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... to reduce the risk of colon cancer, act directly ... have found an association of inherited variations in the ... unable to replicate this finding. Similarly, variations in the ... known to be key in the metabolism of NSAIDs, ...
... that you can personalize.PITTSBURGH, May 22 ... of Computerized Maintenance Management Systems (CMMS) for the healthcare ... personalize.This new product offering is a CMMS application that ... business problems. Users can create their own screen layouts ...
... will be sold online and at retailers across the ... Calif., May 22 On May 22nd Health and ... Inc. (OTC Bulletin Board: ZLUS) announced the launch of ... and supplements. These products, under the name Organix+, by ...
... BEENE GIVES BACK(R) and GQ Magazine Launch Public Service ... GEOFFREY BEENE GIVES BACK(R) and ... celebrity rock stars like nine-time Grammy Award winner, Sheryl ... in areas like cancer, HIV-AIDS, heart disease, Alzheimer,s, genetics ...
... communication among cells tied to this nutritional deficit ... of vitamin D may contribute to cancer development, U.S. ... is loss of communication among cells due to, among ... leader Cedric Garland, an epidemiologist at the Moores Cancer ...
... prevents many complications of chronic disease, experts say, ... strictly control their blood sugar levels also reduce ... British researchers report. , There have been several ... blood sugar levels in diabetic patients in preventing ...
Cached Medicine News:Health News:Four Rivers Software System Launches TMS OnSite Professional 2Health News:Health and Wellness Partners, Inc., A Wholly Owned Subsidiary of Zealous Inc., Launches Organix+ 2Health News:Photos: The Nation's Leading Scientists and Top Rock Stars Shine a Spotlight on the Promise of Medical Research 2Health News:Photos: The Nation's Leading Scientists and Top Rock Stars Shine a Spotlight on the Promise of Medical Research 3Health News:Photos: The Nation's Leading Scientists and Top Rock Stars Shine a Spotlight on the Promise of Medical Research 4Health News:Strict Blood Sugar Control Lowers Heart Risks in Diabetics 2Health News:Strict Blood Sugar Control Lowers Heart Risks in Diabetics 3
The Tissue Cassette Storage Cabinet is made of strong, laminated fiberboard....
The Flash MiniLabeler products can be configured to label microplates, tubes, vials, glass slides, circuit boards and a wide array of small products. Systems perform wrap around (tube or package) lab...
Plastic Block Filing Cabinet is a durable, six-drawer unit that holds up to 1500 slides....
Improving on the technology that the world has come to expect from the original SHUR/Mark® Cassette and Slide Labelers, SHUR/Mark® PLUS offers many added enhancements....
Medicine Products: